Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature
Australasian Journal of Dermatology · 2023
DOI: 10.1111/ajd.14006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Australasian Journal of Dermatology, 2023. Verfasst von Vittorio Tancredi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Mental and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Napoli, Italy. Hauptthemen laut MEDLINE: Down Syndrome, Dermatology, Psoriasis, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Down syndrome (DS) is the most common chromosomal disorder; several dermatological conditions are common in these patients; among them, psoriasis and atopic dermatitis can be frequently encountered. From 2017 to today, we retrospectively identified 4 adults and 3 under 18‐year‐old patients treated with biological drugs, from our research database. The first endpoint of this study was to evaluate whether the biological drugs work in these special population, and a secondary endpoint was to evaluate any loss of efficacy or any side effects during follow‐up. All patients were treated with biological drugs experience resolution of their psoriasis. Mean PASI (Psoriasis Area Severity Index), BSA (Body Surface Area) and DLQI (Dermatology Life Quality Index) at baseline were 20, 16.5 and 25. At week 4, mean PASI, BSA and DLQI decreased, respectively, to 8, 6 and 12, while at week 24, mean values were, respectively, 3, 1.3 and 1. The patients that started therapy earlier, at week 52, do not have signs of recurrence and side effects. We highlighted that no official guidelines exist to approach these patients, from a literature evaluation the most employed drugs are anti‐TNFα and in particular adalimumab. In our experience, the new anti‐interleukin drugs seem to be well‐tolerated, with no sides effect, good compliance and no loss of efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Department of Mental and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Napoli, Italy.
- Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
ORCID-Profile: Gaetano Licata, Dario Buononato
Zitieren
APA
Tancredi, V., Licata, G., Calabrese, G., Buononato, D., De Rosa, A., Argenziano, G., & Gambardella, A. (2023). Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14006
Vancouver
Tancredi V, Licata G, Calabrese G, Buononato D, De Rosa A, Argenziano G, et al. Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature. Australasian Journal of Dermatology. 2023. doi:10.1111/ajd.14006
BibTeX
@article{Tancredi2023,
author = {Tancredi, Vittorio and Licata, Gaetano and Calabrese, Giulia and Buononato, Dario and De Rosa, Alina and Argenziano, Giuseppe and Gambardella, Alessio},
title = {Down syndrome and biological treatments in dermatology: Efficacy and safety in our real‐life experience and review of literature},
journal = {Australasian Journal of Dermatology},
year = {2023},
doi = {10.1111/ajd.14006}
}
EUVIMED